China: LianBio files for proposed IPO of ADS in US

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, has announced the launch of its proposed initial public offering (IPO) of its American depositary shares (ADS). The company has filed a registration statement with the Securities and Exchange Commission (SEC) to offer 20,312,500 ADS at a…

You must be a HMI Subscriber to view this content.

Subscribe Now »